Tracker › Companies › TScan Therapeutics, Inc.
6 No sign of it. We found no public evidence tying TScan Therapeutics, Inc.'s cuts to AI.
Every tracked 2026 layoff at TScan Therapeutics, Inc., newest first. Scores are 0–100: how strongly the public evidence ties the cuts to AI. Sources are linked on each one.
AI score 6/100 (Minimal) · 80% interval 4–7 · evidence grade D · US · Pharma / Chemicals
Stated reason: On September 2, 2026, TScan Therapeutics, Inc. (the “Company”) initiated a prioritization strategy by which the Company will prioritize the preclinical development of its in vivo solid tumor program and pause further enrollment in its Phase 3 ALLOHA-2 TM study of TSC-101. Pursuant to such strategy, the Company also implemented a workforce reduction of approximately 75% of the Company’s workforce (the “Strategic Reorg…
Why 6: Cost-cutting / efficiency · Drivers: industry AI exposure +0.5
Evidence: SEC filing. Signals: attribution 0.0, primary source 0.0, exec statement 0.0, role exposure 0.455, industry exposure 0.712, AI investment 0.0, contrary evidence 0.0 · named roles: Nursing Assistants, Registered Nurses
Headcount basis: not disclosed
Scores are evidence-based estimates from a published model, not findings that AI caused any layoff. Spot something wrong or missing? Tell us.
Other Health Care & Pharma layoffs we track.
Health Care & Pharma · 4,500 workers
Health Care & Pharma · 718 workers
Health Care & Pharma · 628 workers
Health Care & Pharma · 278 workers
Health Care & Pharma · 145 workers
Health Care & Pharma · 130 workers
